Physician profile
Errol B Bryce
NPI 1427077494
$1,990.95
in general payments reported to CMS, 2019-2025
21 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2021: $57.64 · 2022: $366 · 2023: $281 · 2024: $335 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $322.19 | 2024-2025 | Inspire |
| Pfizer INC. | $269.52 | 2019-2025 | |
| Novo Nordisk INC | $211.44 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $195.57 | 2022-2025 | Freestyle Libre |
| Glaxosmithkline, LLC. | $187.58 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corcept Therapeutics | $156.75 | 2025 | Korlym |
| Abbvie INC. | $140.26 | 2021-2024 | Vraylar |
| Eisai INC. | $134.42 | 2024-2025 | |
| Amgen INC. | $72.50 | 2023-2025 | Evenity, Prolia, Otezla |
| Dexcom, INC. | $63.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.98 | 2022-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $38.78 | 2019 | |
| Astellas Pharma US INC | $33.94 | 2025 | Veozah |
| Philips North America LLC | $19.35 | 2024 | (Bo0) Hosp Vent Devices |
| Sanofi-Aventis U.S. LLC | $17.84 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $13.72 | 2023 | Unithroid |
| Ethicon US, LLC | $13.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.04 | 2022 | |
| Lundbeck LLC | $12.97 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $11.73 | 2022 | |
| Lilly USA, LLC | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Errol Bryce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.